# scDrugAtlas: an integrative single-cell drug response database for dissecting tumour heterogeneity in therapeutic efficacy

**Authors:** Yanfei Wu, Wei Huang, Xinda Ren, Hui Liu, Ling Xu

PMC · DOI: 10.1093/database/baag010 · Database: The Journal of Biological Databases and Curation · 2026-02-20

## TL;DR

scDrugAtlas is a database of single-cell drug responses that helps study tumor heterogeneity and drug resistance in cancer.

## Contribution

The novelty is the compilation of over 100 single-cell drug response datasets into a unified database with confidence levels for responses.

## Key findings

- scDrugAtlas includes data from 1023 samples across 77 drugs and 31 cancer types.
- Each drug response is assigned a confidence level based on tissue source and drug exposure factors.
- The database aims to support precision medicine and computational drug resistance research.

## Abstract

Tumour heterogeneity often leads to substantial differences in responses to same drug treatment. The presence of pre-existing or acquired drug-resistant cell subpopulations within a tumour survive and proliferate, ultimately resulting in tumour relapse and metastasis. The drug resistance is the leading cause of failure in clinical tumour therapy. Therefore, accurate identification of drug-resistant tumour cell subpopulations could greatly facilitate the precision medicine and novel drug development. However, the scarcity of single-cell drug response data significantly hinders the exploration of tumour cell resistance mechanisms and the development of computational predictive methods. In this paper, we propose scDrugAtlas, a comprehensive database devoted to integrating the drug response data at single-cell level. We manually compiled more than 100 datasets containing single-cell drug responses from various public resources. The current version comprises large-scale single-cell transcriptional profiles and drug response labels from 1023 samples, across 77 unique drugs and 31 major cancer types. Particularly, we assigned a confidence level to each response label based on the tissue source (primary or relapse/metastasis), drug exposure time, and drug-induced cell phenotype. We believe scDrugAtlas could greatly facilitate the Bioinformatics community for developing computational models and biologists for identifying drug-resistant tumour cells and underlying molecular mechanism.

Database URL: http://drug.hliulab.tech/scDrugAtlas/.

## Full-text entities

- **Genes:** OAS2 (2'-5'-oligoadenylate synthetase 2) [NCBI Gene 4939] {aka AIAISD2}, S100A2 (S100 calcium binding protein A2) [NCBI Gene 6273] {aka CAN19, S100L}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TPM1 (tropomyosin 1) [NCBI Gene 7168] {aka C15orf13, CMD1Y, CMH3, HEL-S-265, HTM-alpha, LVNC9}, C4BPB (complement component 4 binding protein beta) [NCBI Gene 725] {aka C4BP}, ISG15 (ISG15 ubiquitin like modifier) [NCBI Gene 9636] {aka G1P2, IFI15, IMD38, IP17, UCRP, hUCRP}, MALAT1 (metastasis associated lung adenocarcinoma transcript 1) [NCBI Gene 378938] {aka HCN, LINC00047, NCRNA00047, NEAT2, PRO2853, miPEP-52}, IFI6 (interferon alpha inducible protein 6) [NCBI Gene 2537] {aka 6-16, FAM14C, G1P3, IFI-6-16, IFI616}, TUBA1A (tubulin alpha 1a) [NCBI Gene 7846] {aka B-ALPHA-1, LIS3, TUBA3}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, ALDOA (aldolase, fructose-bisphosphate A) [NCBI Gene 226] {aka ALDA, GSD12, HEL-S-87p}, OAS1 (2'-5'-oligoadenylate synthetase 1) [NCBI Gene 4938] {aka E18/E16, IFI-4, IMD100, OIAS, OIASI}, SCNN1A (sodium channel epithelial 1 subunit alpha) [NCBI Gene 6337] {aka BESC2, ENaCa, ENaCalpha, LIDLS3, PHA1B1, SCNEA}, RNF144B (ring finger protein 144B) [NCBI Gene 255488] {aka IBRDC2, PIR2, bA528A10.3, p53RFP}, IFIT1 (interferon induced protein with tetratricopeptide repeats 1) [NCBI Gene 3434] {aka C56, G10P1, IFI-56, IFI-56K, IFI56, IFIT-1}, TAGLN (transgelin) [NCBI Gene 6876] {aka SM22, SM22-alpha, SMCC, TAGLN1, TGLN, WS3-10}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, COL16A1 (collagen type XVI alpha 1 chain) [NCBI Gene 1307] {aka 447AA, FP1572}, IGFBP3 (insulin like growth factor binding protein 3) [NCBI Gene 3486] {aka BP-53, IBP-3, IBP3, IGFBP-3}, IL32 (interleukin 32) [NCBI Gene 9235] {aka IL-32alpha, IL-32beta, IL-32delta, IL-32gamma, NK4, TAIF}
- **Diseases:** melanoma (MESH:D008545), Tumour (MESH:D009369), HNSCC (MESH:D000077195), NSCLC (MESH:D002289), metastasis (MESH:D009362), breast cancer (MESH:D001943)
- **Chemicals:** Vemurafenib (MESH:D000077484), Paclitaxel (MESH:D017239), scDrugAct (-), Cetuximab (MESH:D000068818), Erlotinib (MESH:D000069347), DMSO (MESH:D004121)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** SCC1 — Homo sapiens (Human), Floor of mouth squamous cell carcinoma, Cancer cell line (CVCL_7707), PC9 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_B260), SCC25 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_1682), SCC6 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_7773)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12923164/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12923164/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12923164/full.md

---
Source: https://tomesphere.com/paper/PMC12923164